Company Overview

NeoImmuneTech, Inc. (NIT) is a clinical-stage private biotech company focused on novel immunotherapeutics development.

Founded in 2014, NIT was spun off from Genexine, a leading Korean biotech company listed in KOSDAQ. Based in Rockville, Maryland, NIT has the core competency of global clinical development and business development actively networking with many global leading research and development organizations.

NIT's lead product is IL-7-hyFc (NT-I7; Hyleukin) optimally designed as an immuno-oncology agent to reconstitute and enhance anti-tumoral T cell immunity. NT-I7 consists of homodimeric Interleukin-7 (IL-7) molecules, the homeostatic cytokines to enhance the number and the function of T cells, biologically fused with IgD/IgG4 immunoglobulin domain as a safe and effective long-acting carrier.

NIT is currently under Phase I clinical trial of NT-I7, aiming at developing not only the first-in-class treatment of lymphopenia as a monotherapy, but also breakthrough "enabling" cancer immunotherapeutics, which may substantially enhance the anti-tumor efficacy of the conventional cancer treatments and/or novel immunotherapies harnessing T cell immunity as a combination therapy.